Literature DB >> 6203617

Substance P immunoreactivity in the post-mortem parkinsonian brain.

O Tenovuo, U K Rinne, M K Viljanen.   

Abstract

The amount of substance P immunoreactivity (SPI) was measured by radioimmunoassay from the cerebral cortex, caudate nucleus, putamen, pallidum, substantia nigra, hypothalamus, nucleus accumbens, amygdala and hippocampus from autopsy brains. The whole material consisted of 42 parkinsonian patients and 31 controls. The amount of SPI was significantly decreased in the substantia nigra of the parkinsonian brain. There was also a significant decrease of SPI in the putamen of those parkinsonian patients, who had not received levoDOPA treatment. The levels of SPI in the other brain regions studied did not show any difference between parkinsonian patients and controls. The results obtained suggest that substance P (SP) may have a role in the pathophysiology of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203617     DOI: 10.1016/0006-8993(84)90217-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain.

Authors:  W S Young; T I Bonner; M R Brann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

2.  Determination of beta-endorphin and substance P in small volumes of human cerebrospinal fluid.

Authors:  K Henning; T M Wallasch; H Przuntek
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

Review 3.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 4.  The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders.

Authors:  Nick Pantaleo; Wayne Chadwick; Sung-Soo Park; Liyun Wang; Yu Zhou; Bronwen Martin; Stuart Maudsley
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

Review 5.  Demystifying the Neuroprotective Role of Neuropeptides in Parkinson's Disease: A Newfangled and Eloquent Therapeutic Perspective.

Authors:  Tapan Behl; Piyush Madaan; Aayush Sehgal; Sukhbir Singh; Hafiz A Makeen; Mohammed Albratty; Hassan A Alhazmi; Abdulkarim M Meraya; Simona Bungau
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

6.  Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.

Authors:  Emma Thornton; Robert Vink
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

7.  Cutaneous neuropathy in Parkinson's disease: a window into brain pathology.

Authors:  Kathrin Doppler; Sönke Ebert; Nurcan Uçeyler; Claudia Trenkwalder; Jens Ebentheuer; Jens Volkmann; Claudia Sommer
Journal:  Acta Neuropathol       Date:  2014-05-01       Impact factor: 17.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.